or s.c. (subcutaneous) injection [1, 2, 27, 31, 35] Thereby, the recommended dosing regimen of ENR conventional injection was administrated a single 2.5 ~ 5 mg/kg b.w. per day or twice a day, meaning that a course of treatment needs multiple dosing [40] . Obviously, in the clinical application the conventional injection caused a lot of inconvenience, for example, repeated stress response maybe worsen animals' illness or result in more disease, and the drugs' action was not sufficient when it was in peaks and valleys, what's more, frequency administration spent great human, financial and material resources.
Introduction
Enrofloxacin (ENR), a synthetic agent of fluoroquinolone developed specifically for veterinary use, exhibits a broad spectrum of antibacterial activity [13] . It is active at low concentrations, compared with other classes of antimicrobial agents [14, 22] . Similar to other fluoroquinolones, ENR produce their bactericidal properties by inhibiting the type IIA topoisomerase (DNA gyrase/topoisomerase II and topoisomerase IV), thereby preventing supercoiling and synthesis of bacterial DNA [9] . Due to the excellent antibacterial scope and activity, this kind of drugs has been widely applied in veterinary clinical since the date of listing.
Studies on the in vivo process of ENR conventional injection in animals showed that it had good absorption and high drug concentrations within the organism by injection, then it's suitable for treatment and prevention of bacterial infection in tissues [6, 10, 15, 36] . But the terminal elimination half-life (t 1/2λz ) in pigs was less than 9 ~ 12 h after i.m. (intramuscular) To avoid the disadvantages of the ENR conventional injection, we developed a thermo sensible in situ forming gel with moderate poloxamers (P407 and P188) for ENR, which have the advantage of being injected as a liquid that changes into a solid gel immediately after injection. Through repeated experiments, we achieved that the gelation temperatures of the form we developed were 34 ± 0.5°C, and the gelation times were 7.5 ± 0.5 s in 37°C, in vitro release was about 40.7% in 24 h, and followed by sustained release was up to 100% within 144 h, which confirmed that the in vitro release of this form was good. Therefore, the objectives of this study were to evaluate pharmacokinetic characteristics of this form in pigs following a single IM administration, and then promote the use of it in veterinary clinical treatment and prevention.
Materials and methods

Drugs and reagents
98.5% (w/v) ENR was purchased from Guobang Pharmaceutical Corporation (Zhejiang, China). 99.9% (w/v) ENR analytical standards (Batch number, H0081206) were purchased from the China Institute of Veterinary Drug Control (Beijing, China). 5% (w/v) ENR injection was purchased from Hengtong Animal Pharmacy (Sichuan, China). 20% (w/v) ENR injectable in situ forming gel (Gelation temperatures, 33.5 ~ 34.5°C) was homemade with moderate poloxamers (P407 and P188). Acetonitrile was of high-performance liquid chromatography grade and purchased from Merck Corporation (Darmstadt, Germany). All other reagents used for extraction and analysis were analytical reagent grade or better and were commercially available.
Animals
Pharmacokinetics evaluation was performed on twelve clinically-healthy crossbred pigs (Duroc × Landrace × Yorkshire) weighing 10 ± 1.6 kg. In this trial, they were housed in semicontained pens with access to water ad libitum and a commercial non-medicated chow at scheduled times. Pigs enrolled in the studies had no previous administration to any antibiotic and no drugs were given to the animals during the acclimation or experimental periods. All experimental procedures involving animals were conducted following the guidelines of Nanjing Agricultural University (Nanjing, China) Animal Ethics Committee.
Experimental design
When pigs were housed in experiment condition for a week of environmental adaptation, they were randomly divided into two groups (6 pigs per group, half mare and half female). Prior to ENR administration, all pigs were weighed and blood samples were taken from the precaval vein for control. For group one, each pig was administered a single i.m. injection in gluteal of 20 mg/kg b.w. ENR in situ forming gel and blood samples were collected from the precaval vein of each pig and collected in tubes containing heparin as anticoagulant at 0.25, 0.5, 2, 5, 9, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168 and 180 h after dosing. For the other group, each pig was administered a single i.m. injection in gluteal of 5 mg/kg b.w. ENR conventional injection and blood samples were taken from the precaval vein of each pig and collected in tubes with anticoagulant (heparin) at 0.25, 0.5, 2, 5, 9, 12, 24, 36, 48, 60, 72, 84 and 96 h after dosing. Samples were centrifuged within 1 h after collection and plasma samples were stored frozen (-20°C) until analysis. All the samples were analyzed within one week after the experiments.
Analytical method
Apparatus conditions: The HPLC system (Agilent 1200 series; Agilent Technologies Co. Ltd., Palo Alto, Santa Clara, CA, USA) comprised a G1311A quaternary pump, a G1328B MAN injector, a G1314B UV detector, a G1316A column heater and online/offline analysis software. The UV detector was set to monitor 278 nm. Chromatographic separations were performed on Eclipse XDB-C18 column (5-μm, 250 × 4.6 mm). The column temperature was maintained at 35°C. The composition of the mobile phase was phosphoric acid (adjust pH to 3.5 with triethylamine; 0.1 M)-acetonitrile (84: 16, v/v). The flow rate of the mobile phase was set to 0.8 mL/min.
Sample preparation:
The extraction method was performed as described by Guo M [18] with some modifications. Briefly, the frozen plasma samples (0.2 mL) were thawed at room temperature and added 2 mL of methylene chloride. The mixture was mechanically shaken for 3 min and centrifuged for 10 min at 8000 × g, and then the lower layer was manually transferred into a tube. Then the organic layer was evaporated at 50°C under nitrogen and the residue was reconstituted in 0.2 mL of mobile phase. At last, the samples were vortex mixed for 5 min, centrifuged at 12000 × g for 10 min and 20 μL volumes was injected into HPLC system.
Pharmacokinetic data analysis
ENR plasma concentration verse time date of each animal was subjected to the non-compartmental analysis (NCA) using the computer program WinNonlin version 5.2 (Pharsight, CA, USA). Lambda z is a first-order rate constant associated with the terminal (log linear) segment of the curve. It was estimated by the linear regression of the terminal data points. The terminal elimination half-life (t 1/2λz ) was calculated by t 1/2λz = 0.693/λz. Areas under the plasma concentration-time curves (AUC 0→∞ and AUC 0→t ) were calculated by the method of trapezoids. Peak plasma concentrations (C max ) of drug and times to reach peak concentration (t max ) were determined from the individual plasma concentration-time curves.
Statistical analysis
All data were presented as mean ± standard deviation (SD). The pharmacokinetic parameters determined were compared by one-way analysis of variance using statistical software (SPSS version 12; SPSS Inc., Chicago, IL, USA). In all cases, p < 0.05 was considered statistically significant.
Results
No adverse reaction or apparent sign of toxic effects related to ENR were observed in the days following injection. The serum concentration vs. time data of ENR injectable in situ forming In this study, blood concentrations of ENR in situ forming gel were monitored over 180 h while the conventional injections were just 72 h. There were significant differences (p < 0.01) between ENR in situ forming gel and conventional injection in pharmacokinetic parameters t 1/2λz . The terminal elimination halflife calculated for ENR in situ gel 42.92 ± 9.80 h was significantly higher than that of the conventional injection which was 9.17 ± 0.61 h. The area under the blood concentration vs. time curve (AUC) of ENR in situ gel was 48.00 ± 6.44 μg·h/mL, obtained for hours 0 to 180 by the trapezoid rule and normalized for injected dose, while that of conventional one was 19.96 ± 4.07 μg·h/mL. The mean residence time (MRT) of ENR in situ gel and conventional injection were 49.39 ± 8.97 h and 11.75 ± 0.90 h, respectively. The C max value of ENR injectable in situ forming gel had a similar level with the conventional injection, which was 1.71 ± 0.24 μg/mL reached after 2.50 ± 1.22 h while the conventional injection was 1.76 ± 0.32 μg/mL reached after 2.00 ± 0.00 h.
Discussion
In our study, a novel approach based on thermoreversible in situ forming gel with poloxamers for prolonged release of ENR had been implemented. The in vivo pharmacokinetic results showed that the mean residence time (MRT) and the terminal elimination half-life (t 1/2λz ) of the drugs we developed were respectively 49.39 ± 8.97 h and 42.92 ± 9.80 h after a single 20 mg/kg b.w. i.m. injection. Significantly, the in vivo characteristics of ENR thermoreversible in situ forming gel we developed in pigs were superior to that of the ENR conventional injection [2, 27] , and also more ideal than the reported results of ENR sustainedrelease injection [37, 39] . [37] found that at the dose of 18.75 mg/ kg b.w. under i.m. injection, the t 1/2λz value of ENR long-acting injection solution was 19.47 h, and so on. Though all these dosing regimens (t 1/2λz , 18.95 ~ 26.6 h) have improved compare to the recommended (t 1/2λz , 9 ~ 12 h), the t 1/2λz value is still further lower than that of ENR long-acting forms in our study (t 1/2λz = 42.92 h).
Due to the addition of poloxamer 407 (P407), thermosensible in situ gel system has the reversal thermal characteristics, and addition of proper poloxamer 188 (P188) could adjust its gelation temperatures [7, 12, 38] . The preparation of this kind of thermosensible in situ gel often adopts the " Cold method " [34] , which is fully equipped with the feasibility of industrial production. In medicine, multiple related preparations are in the process of new drug application (NDA). Some other additives, such as carboxymethylcellulose sodium (CMC-Na), polyvinylpyrrolidone (PVP), carbomer, and even sodium chloride (NaCl), can affect the gelation strength and gelation time of thermosensible in situ gel. Because the patent of this drug is in the examination period, it is inconvenient to discuss its formula in this paper. But the results indicated that this prescription composition was ideal.
The characteristics of antibacterial activity of the fluoroquinolones and the relationship between the MIC and the blood drug concentration have been in-depth study [4] . As the ratio of fluoroquinolones concentration to MIC increases from 1:1 to the optimal bactericidal concentration (usually 10:1), the fluoroquinolones presents concentration-dependent killing effect. The concentration-dependent killing effect may plateau off when the ratio of fluoroquinolones concentration to MIC reaches [3, 5] .
In our study, the mean plasma concentration following the injection of in situ gel in pigs was 0.13 μg/mL at 96 h, 0.07 μg/mL at 144 h, indicating that the drugs we developed had much longer acting time than common injection. In spite of the dosage of ENR in situ gel was four times as large as that of ENR conventional injection; the C max of them had a similar level. And the C max /MIC ratio of ENR in situ gel was less than 20, thus avoiding excessive concentration result in bacteriostatic. This can be explained with the higher distribution volume that leads to lower peak plasma levels within the pigs. Therefore, when compared with the control injection, the in situ gel can lead to a reduction of the severity of systemic side effects induced by ENR. Furthermore, to maximize clinical efficacy and reduce selection of resistant bacteria, C max /MIC ratio ≥ 10 : 1 or AUC/MIC 90 ratio ≥ 125 : 1 may be required [11, 16, 17, 19] . In our study, the AUC of ENR in situ gel in pigs which was 48.00 ± 6.44 μg·h/mL at a single 20 μg/mL b.w. dose. Obviously, the AUC/MIC 90 ratio of ENR in situ gel was more than 125, suggesting that the ENR in situ gel had a better clinical efficacy.
In conclusion, the C max of ENR in situ gel was in the range of ideal bactericidal concentration, and the values of t 1/2λz and MRT were greatly extended, which could maintain the effective blood drug concentrations for a long time. Therefore, following a single i.m. administration, the pharmacokinetic characteristics of ENR in situ gel in pigs were ideal. On the other hand, the ratios of C max /MIC and AUC/MIC 90 suggested that the ENR in situ gel had a better clinical efficacy. According to this reasonable formulation design, it is worth popularizing in clinical application.
